Literature DB >> 28434510

PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?

Sylvie Lantuejoul1, Nolwenn Le Stang2, Francesca Damiola3, Arnaud Scherpereel4, Francoise Galateau-Sallé5.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28434510     DOI: 10.1016/j.jtho.2017.03.018

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  6 in total

1.  New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Authors:  F Galateau Salle; N Le Stang; A G Nicholson; D Pissaloux; A Churg; S Klebe; V L Roggli; H D Tazelaar; J M Vignaud; R Attanoos; M B Beasley; H Begueret; F Capron; L Chirieac; M C Copin; S Dacic; C Danel; A Foulet-Roge; A Gibbs; S Giusiano-Courcambeck; K Hiroshima; V Hofman; A N Husain; K Kerr; A Marchevsky; K Nabeshima; J M Picquenot; I Rouquette; C Sagan; J L Sauter; F Thivolet; W D Travis; M S Tsao; B Weynand; F Damiola; A Scherpereel; J C Pairon; S Lantuejoul; V Rusch; N Girard
Journal:  J Thorac Oncol       Date:  2018-04-30       Impact factor: 15.609

2.  Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.

Authors:  Giulio Metro; Diego Signorelli; Elio G Pizzutilo; Laura Giannetta; Giulio Cerea; Miriam Garaffa; Alex Friedlaender; Alfredo Addeo; Martina Mandarano; Guido Bellezza; Fausto Roila
Journal:  Hum Vaccin Immunother       Date:  2021-05-18       Impact factor: 3.452

3.  A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.

Authors:  Tadashi Sakane; Takayuki Murase; Katsuhiro Okuda; Hisashi Takino; Ayako Masaki; Risa Oda; Takuya Watanabe; Osamu Kawano; Hiroshi Haneda; Satoru Moriyama; Yushi Saito; Takeshi Yamada; Ryoichi Nakanishi; Hiroshi Inagaki
Journal:  Oncotarget       Date:  2018-01-08

Review 4.  Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting.

Authors:  Fabio Nicolini; Martine Bocchini; Davide Angeli; Giuseppe Bronte; Angelo Delmonte; Lucio Crinò; Massimiliano Mazza
Journal:  Cancers (Basel)       Date:  2020-04-08       Impact factor: 6.639

5.  P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment.

Authors:  Federica Pezzuto; Francesca Lunardi; Luca Vedovelli; Francesco Fortarezza; Loredana Urso; Federica Grosso; Giovanni Luca Ceresoli; Izidor Kern; Gregor Vlacic; Eleonora Faccioli; Marco Schiavon; Dario Gregori; Federico Rea; Giulia Pasello; Fiorella Calabrese
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

6.  Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.

Authors:  Takuya Watanabe; Katsuhiro Okuda; Takayuki Murase; Satoru Moriyama; Hiroshi Haneda; Osamu Kawano; Keisuke Yokota; Tadashi Sakane; Risa Oda; Hiroshi Inagaki; Ryoichi Nakanishi
Journal:  Oncotarget       Date:  2018-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.